Pfizer’s $11 billion Array purchase shows oncology assets continue to drive pharma transactions
The world’s largest life sciences company demonstrates that it is still a major presence in the M&A landscape, despite its stated focus on organic growth.
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.